CA3168103A1 - Compounds and compositions for use in treating skin disorders - Google Patents

Compounds and compositions for use in treating skin disorders

Info

Publication number
CA3168103A1
CA3168103A1 CA3168103A CA3168103A CA3168103A1 CA 3168103 A1 CA3168103 A1 CA 3168103A1 CA 3168103 A CA3168103 A CA 3168103A CA 3168103 A CA3168103 A CA 3168103A CA 3168103 A1 CA3168103 A1 CA 3168103A1
Authority
CA
Canada
Prior art keywords
compound
alkyl
halo
phase
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3168103A
Other languages
English (en)
French (fr)
Inventor
Xinyuan Wu
Bertrand L. Chenard
Nili Claudia SCHUTZ
Dov Terkieltaub
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kamari Pharma Ltd
Original Assignee
Kamari Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kamari Pharma Ltd filed Critical Kamari Pharma Ltd
Publication of CA3168103A1 publication Critical patent/CA3168103A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3168103A 2020-01-29 2021-01-28 Compounds and compositions for use in treating skin disorders Pending CA3168103A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062967500P 2020-01-29 2020-01-29
US62/967,500 2020-01-29
PCT/US2021/015449 WO2021154966A1 (en) 2020-01-29 2021-01-28 Compounds and compositions for use in treating skin disorders

Publications (1)

Publication Number Publication Date
CA3168103A1 true CA3168103A1 (en) 2021-08-05

Family

ID=77079457

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3168103A Pending CA3168103A1 (en) 2020-01-29 2021-01-28 Compounds and compositions for use in treating skin disorders

Country Status (12)

Country Link
US (2) US11807621B2 (cg-RX-API-DMAC7.html)
EP (2) EP4574822A3 (cg-RX-API-DMAC7.html)
JP (2) JP7785004B2 (cg-RX-API-DMAC7.html)
KR (1) KR102735703B1 (cg-RX-API-DMAC7.html)
CN (2) CN115335050B (cg-RX-API-DMAC7.html)
AU (1) AU2021212754B2 (cg-RX-API-DMAC7.html)
CA (1) CA3168103A1 (cg-RX-API-DMAC7.html)
ES (1) ES3032872T3 (cg-RX-API-DMAC7.html)
HU (1) HUE071972T2 (cg-RX-API-DMAC7.html)
IL (2) IL295088B2 (cg-RX-API-DMAC7.html)
PL (1) PL4096661T3 (cg-RX-API-DMAC7.html)
WO (1) WO2021154966A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4574822A3 (en) 2020-01-29 2025-08-27 Kamari Pharma Ltd. Compounds and compositions for use in treating skin disorders
WO2023214375A1 (en) * 2022-05-05 2023-11-09 Kamari Pharma Ltd. Methods of treating dermatological conditions and symptoms thereof
CN117164527B (zh) * 2022-05-25 2026-02-17 大连理工大学 一种钒催化杂环芳香腈水解制备杂环芳香酰胺的方法
WO2024099404A1 (zh) 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 一种含氮螺环类化合物、药物组合物以及其用途
CN120202198A (zh) * 2022-11-10 2025-06-24 北京普祺医药科技股份有限公司 一种具有软药性质的硫醚类化合物、药物组合物及其用途
CN117624036A (zh) * 2023-10-30 2024-03-01 爱斯特(成都)生物制药股份有限公司 一种制备6-溴-3-氟-2-吡啶甲醛的方法

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798053A (en) 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US4183931A (en) 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
DE2961415D1 (en) 1978-05-20 1982-01-28 Bayer Ag Heteroaryloxy-acetamides, process for their preparation and their use as herbicides
US4461896A (en) 1979-02-07 1984-07-24 Norwich Eaton Pharmaceuticals, Inc. 1-[Acylthio) and (mercapto)-1-oxoalkyl]-1,2,3,4-tetrahydroquinoline-2-carboxylic acids
DE3018075A1 (de) 1980-05-10 1981-11-12 Bayer Ag, 5090 Leverkusen Mittel zur regulierung des pflanzenwachstums, deren herstellung und deren verwendung
JPS56158702A (en) 1980-05-12 1981-12-07 Nippon Tokushu Noyaku Seizo Kk Herbicide
US4273927A (en) 1980-08-14 1981-06-16 Morton-Norwich Products, Inc. Converting enzyme inhibitor
DE3038652A1 (de) 1980-10-13 1982-05-19 Bayer Ag, 5090 Leverkusen 5-chlor-benzoxazol-2-yl-oxyessigsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
DE3038599A1 (de) 1980-10-13 1982-05-19 Bayer Ag, 5090 Leverkusen Substituierte benzazol-2-yl-oxyessigsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
US4509949A (en) 1983-06-13 1985-04-09 The B. F. Goodrich Company Water thickening agents consisting of copolymers of crosslinked acrylic acids and esters
DE3418168A1 (de) 1984-05-16 1985-11-21 Bayer Ag, 5090 Leverkusen 6-chlorbenzazolyloxyacetamide
DE3422861A1 (de) 1984-06-20 1986-01-02 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von heteroaryloxyacetamiden
US5087445A (en) 1989-09-08 1992-02-11 Richardson-Vicks, Inc. Photoprotection compositions having reduced dermal irritation
US5196427A (en) 1990-09-13 1993-03-23 Eli Lilly And Company 3-aryl-4(3H) quinazolinone CCK antagonists and pharmaceutical formulations thereof
US5075313A (en) 1990-09-13 1991-12-24 Eli Lilly And Company 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof
DE4218433A1 (de) 1992-06-04 1993-12-09 Bayer Ag Fluorbenzoxazolyloxyacetamide
DE4219246A1 (de) 1992-06-12 1993-12-16 Bayer Ag Neue 2-(7-Chlor-2-benzoxazolyloxy)-acetamide
DE4230903A1 (de) 1992-09-16 1994-03-17 Bayer Ag Fluorbenzthiazolyloxyacetamide
FR2707639B1 (fr) 1993-06-30 1995-10-13 Pf Medicament Nouveaux composés indoliques dérivés d'arylamines comme ligands sélectifs des récepteurs 5HT1D et 5HT1B.
US5756502A (en) 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
DE19615262A1 (de) 1996-04-18 1997-10-23 Bayer Ag Heteroverknüpfte Phenylglycinolamide
ES2184960T3 (es) 1996-05-15 2003-04-16 Pfizer Nuevas pirimidin-4-onas-(5,6)-heteroaril condensadas 2,3 disustituidas.
BR9709085A (pt) 1996-05-15 1999-08-03 Pfizer Novas 2,3-dissubstituído-4(3H)-quinazolinonas
US6380204B1 (en) 1997-02-28 2002-04-30 Pfizer Inc Atropisomers of 3-heteroaryl-4(3H)-quinazolinones for the treatment of neurodegenerative and CNS-trauma related conditions
PT968194E (pt) 1997-02-28 2004-08-31 Pfizer Prod Inc Atropisomeros de 3-aril-4(3h)-quinazolinonas e sua utilizacao como antagonistas dos receptores ampa
ATE229004T1 (de) 1997-03-31 2002-12-15 Korea Res Inst Chem Tech Chinolinische sulfid-derivate als nmda rezeptor- antagonisten und verfahren zu ihrer herstellung
US6060479A (en) 1997-06-09 2000-05-09 Pfizer Inc Quinazoline-4-one AMPA antagonists
US6627755B1 (en) 1997-06-09 2003-09-30 Pfizer Inc Quinazolin-4-one AMPA antagonists
IL125950A0 (en) 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
US6323208B1 (en) 1997-09-05 2001-11-27 Pfizer Inc Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones
JPH11279158A (ja) 1998-02-09 1999-10-12 Pfizer Prod Inc キナゾリン―4―オン誘導体の製造方法
JP4327915B2 (ja) 1998-03-30 2009-09-09 株式会社デ・ウエスタン・セラピテクス研究所 スルフォンアミド誘導体
DE60017157T2 (de) 1999-09-16 2005-12-22 Curis, Inc., Cambridge Vermittler von igel signalwegen, deren zusammenstellungen und verwendungen
US20030219806A1 (en) 2000-02-22 2003-11-27 Millennium Pharmaceuticals, Inc. Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor
US20020156253A1 (en) 2000-06-26 2002-10-24 Curtis Rory A.J. 48000 and 52920, novel human calcium channels and uses thereof
GB2372993A (en) 2000-11-03 2002-09-11 Smithkline Beecham Plc Vanilloid Receptor 6
IL155613A0 (en) 2000-12-01 2003-11-23 Bristol Myers Squibb Co Novel human nucleic acid molecules and polypeptides emcoding a novel human ion channel expressed in spinal cord and brain
EP1399558A2 (en) 2001-06-13 2004-03-24 Novartis AG Vanilloid receptor-related nucleic acids and polypeptides
WO2003043961A2 (en) 2001-11-19 2003-05-30 Iconix Pharmaceuticals, Inc. Modulators of rho c activity
US20040110777A1 (en) 2001-12-03 2004-06-10 Annis Gary David Quinazolinones and pyridinylpyrimidinones for controlling invertebrate pests
US20040009537A1 (en) 2002-01-11 2004-01-15 Jack Roos Methods of modulating and of identifying agents that modulate intracellular calcium
WO2003106435A1 (en) 2002-06-18 2003-12-24 Sankyo Company, Limited Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
US6649638B1 (en) 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
WO2004041755A2 (en) 2002-11-04 2004-05-21 Nps Pharmaceuticals, Inc. Quinazolinone compounds as calcilytics
DE10330157A1 (de) 2003-07-04 2005-02-03 Zf Friedrichshafen Ag Lastschaltgetriebe für Baumaschinen, insbesondere für Baggerlader und Telehandler
GB0317516D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
CA2531766C (en) 2003-09-11 2012-11-27 Tibotec Pharmaceuticals Ltd. Entry inhibitors of the hiv virus
DE10351087A1 (de) 2003-10-31 2005-05-25 Bayer Technology Services Gmbh Feste Wirkstoff-Formulierung
EP1687306A1 (en) 2003-11-14 2006-08-09 MERCK SHARP & DOHME LTD. Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1)
AP2331A (en) 2003-12-22 2011-12-05 Pfizer Triazole derivatives as vasopressin antagonists.
WO2005086895A2 (en) 2004-03-08 2005-09-22 Wyeth Ion channel modulators
US20050202539A1 (en) 2004-03-11 2005-09-15 Hydra Biosciences System for screening eukaryotic membrane proteins
KR20070012407A (ko) 2004-04-15 2007-01-25 아스텔라스세이야쿠 가부시키가이샤 2-아미노피리미딘 유도체
JP2008501707A (ja) 2004-06-04 2008-01-24 アイコス、コーポレーション マスト細胞障害を処置するための方法
KR101111099B1 (ko) 2004-09-09 2012-02-17 아바야 테크놀러지 코퍼레이션 네트워크 트래픽 보안 방법들 및 시스템들
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
GB0503646D0 (en) * 2005-02-22 2005-03-30 Novartis Ag Organic compounds
US8916550B2 (en) 2005-05-09 2014-12-23 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
EP2392328A1 (en) 2005-05-09 2011-12-07 Hydra Biosciences, Inc. Compounds for modulating TRPV3 Function
GB0509573D0 (en) 2005-05-11 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
AU2006244027A1 (en) 2005-05-11 2006-11-16 Merck Sharp & Dohme Limited 2,3-substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilloid-1 receptor (VR1)
TW200726767A (en) * 2005-07-04 2007-07-16 Astrazeneca Ab Chemical compounds 2
EP1945222B1 (en) 2005-11-02 2012-12-26 Bayer Pharma Aktiengesellschaft Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
US20100152209A1 (en) 2005-11-04 2010-06-17 Hydra Biosciences Inc. Compounds for Modulating TRPV3 Function
WO2008033564A1 (en) 2006-09-15 2008-03-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
US20090306163A1 (en) 2008-06-10 2009-12-10 Pamela Renee Lipkin Topical compositions comprising imidazolidinedione analogs and their use to treat or prevent the appearance of skin wrinkling
KR101034300B1 (ko) 2008-12-02 2011-05-16 고려대학교 산학협력단 Trpv3 활성 억제 약물 및 이의 활용
US8318928B2 (en) * 2008-12-15 2012-11-27 Glenmark Pharmaceuticals, S.A. Fused imidazole carboxamides as TRPV3 modulators
US8318759B2 (en) * 2009-02-18 2012-11-27 Hoffmann-La Roche Inc. Pyrrolidine derivatives as NK3 receptor antagonists
EP2630138B1 (en) * 2010-10-21 2015-06-03 Bayer Intellectual Property GmbH 1-(heterocyclic carbonyl)-2-substituted pyrrolidines and their use as fungicides
WO2012058132A1 (en) * 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
TW201336847A (zh) 2012-02-07 2013-09-16 Taiho Pharmaceutical Co Ltd 喹啉基吡咯并嘧啶化合物或其鹽
US20140018435A1 (en) 2012-06-06 2014-01-16 University Of Illinois Chicago Transdermal Delivery of Therapeutic Agents Using Poly (Amidoamine) Dendrimers
TWI710558B (zh) 2013-05-01 2020-11-21 瑞士商赫孚孟拉羅股份公司 二雜芳基化合物及其用途
US9617214B2 (en) * 2013-11-08 2017-04-11 The Translational Genomics Research Institute Compounds for cognitive enhancement and methods of use thereof
CA2932396C (en) * 2013-12-03 2022-03-29 Janssen Pharmaceutica Nv Benzamide derivative useful as fasn inhibitors for the treatment of cancer
JP2017100948A (ja) 2014-04-01 2017-06-08 大日本住友製薬株式会社 4−アリールイミダゾール誘導体
EP3204379B1 (en) * 2014-10-10 2019-03-06 Genentech, Inc. Pyrrolidine amide compounds as histone demethylase inhibitors
WO2016172631A2 (en) * 2015-04-24 2016-10-27 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof
CN107417687A (zh) 2016-05-24 2017-12-01 中国科学院上海药物研究所 五元杂环并[3,4‑d]哒嗪酮类化合物、其制备方法、药物组合物及其应用
CN108570038B (zh) 2017-03-08 2021-09-28 中国科学院上海药物研究所 二氢喹喔啉类溴结构域识别蛋白抑制剂及制备方法和用途
EP4574822A3 (en) 2020-01-29 2025-08-27 Kamari Pharma Ltd. Compounds and compositions for use in treating skin disorders
WO2023214375A1 (en) * 2022-05-05 2023-11-09 Kamari Pharma Ltd. Methods of treating dermatological conditions and symptoms thereof

Also Published As

Publication number Publication date
US20240124413A1 (en) 2024-04-18
EP4096661C0 (en) 2025-04-02
US12435061B2 (en) 2025-10-07
JP2023512664A (ja) 2023-03-28
WO2021154966A1 (en) 2021-08-05
EP4096661B1 (en) 2025-04-02
EP4096661A1 (en) 2022-12-07
IL295088A (en) 2022-09-01
CN118702672A (zh) 2024-09-27
EP4574822A2 (en) 2025-06-25
ES3032872T3 (en) 2025-07-28
KR102735703B1 (ko) 2024-11-28
EP4574822A3 (en) 2025-08-27
AU2021212754A1 (en) 2022-08-04
IL295088B2 (en) 2026-04-01
EP4096661A4 (en) 2024-03-06
KR20220139299A (ko) 2022-10-14
US20220332697A1 (en) 2022-10-20
JP7785004B2 (ja) 2025-12-12
US11807621B2 (en) 2023-11-07
HUE071972T2 (hu) 2025-10-28
NZ790364A (en) 2025-12-19
IL324069A (en) 2025-12-01
AU2021212754B2 (en) 2026-05-21
PL4096661T3 (pl) 2025-09-01
IL295088B1 (en) 2025-12-01
CN115335050A (zh) 2022-11-11
BR112022014933A2 (pt) 2022-09-20
CN115335050B (zh) 2024-05-17
JP2025175030A (ja) 2025-11-28

Similar Documents

Publication Publication Date Title
US12435061B2 (en) Compounds and compositions for use in treating skin disorders
TWI444378B (zh) 具有β-分泌酶抑制作用之含硫雜環衍生物及其用途
AU2015339196A1 (en) Substituted tetrahydropyrans and method of use
KR20180073689A (ko) Ret의 저해제
WO2018170204A1 (en) 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof
WO2019154252A1 (zh) 取代的烟酰胺类化合物及药物组合物及其用途
CN114667289A (zh) 杂芳基血浆激肽释放酶抑制剂
CN105579447A (zh) 乙炔基衍生物
EP4201924B1 (en) Ire1 small molecule inhibitors
WO2025241047A1 (en) Inhibitors of lactate dehydrogenase, compositions comprising the inhibitor, and methods of use thereof
US11401261B2 (en) 2-heteroaryl aminoquinazolinone derivative
BR122024002638A2 (pt) Compostos, composições compreendendo os mesmos, e usos destes
EP3085695A1 (en) Substituted triazinone compound and t-type calcium channel inhibitor
BR112022014933B1 (pt) Compostos ou sal farmaceuticamente aceitável dos mesmos e usos dos mesmos
BR122024002638B1 (pt) Compostos e usos destes
JP2020519694A (ja) オレキシン受容体アンタゴニス
HK40082455A (en) Compounds and compositions for use in treating skin disorders
EP4140985A1 (en) 2-heteroarylaminoquinazolinone derivative
HK40082455B (en) Compounds and compositions for use in treating skin disorders
CN102408417A (zh) 2-取代乙烯磺酸酯类化合物及其制备方法和应用
CN119019379B (zh) 一种异呋喃酮类化合物及其药物组合物和用途
CN117651698A (zh) 吡啶酮mk2抑制剂及其用途
WO2025241048A1 (en) Inhibitors of lactate dehydrogenase, compositions comprising the inhibitor, and methods of use thereof
CA3025129A1 (en) N-[3-[2-amino-5-(1,1-difluoroethyl)-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]oxazin-7a-yl]-4-fluoro-phenyl]-5-(trifluoromethyl)pyridine-2-carboxamide and its (4ar,5s,7as) isomer as a selective bace1 inhibitor for treating e.g. alzheimer's disease
CN120817949A (zh) 作为wrn抑制剂的化合物及其应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220929

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240715

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240909

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20240924

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20240927

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20241105

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250127

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250208

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250210

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250211

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250211

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250627

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250627

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251006

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251028

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251230

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260121

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260121

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260121

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260130

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260130

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260311